DanielJLandsburgMD

PubMed

• 52 citations
  Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
  Victor M. Orellana-Noia, Daniel R Reed, A. Mccook, Jeremy M Sen, Christian M Barlow
  Blood. 2021-09-27
• 313 citations
  Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
  Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander
  Haematologica. 2018-05-01
• 52 citations
  T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
  Guido Ghilardi, Joseph A Fraietta, James N Gerson, Vivianna M Van Deerlin, Jennifer J D Morrissette
  Nature Medicine. 2024-04-01

Journal Articles

• Can We Exploit the Molecular Heterogeneity of Aggressive B Cell Lymphomas into Effective New Therapies  
  Daniel J Landsburg, Brad S Kahl, Clinical Lymphoma, Myeloma, & Leukemia
• Non-Viral RNA Chimeric Antigen Receptor Modified T Cells in Patients with Hodgkin Lymphoma  
  Stephan A Grupp, Sunita Dwivedy Nasta, Susan R Rheingold, Daniel J Landsburg, Carl H June, Jakub Svoboda, Stephen J Schuster, Saar I Gill, David L Porter, Bruce L Levine, Blood

Abstracts/Posters

• Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas
  Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement
  Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...
  Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0410
  Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
  Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
  Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...
  Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience
  Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malig...
  Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications
  Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Real World Outcomes of Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation and Receive Commerci...
  Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients
  Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis
  Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Clinical Outcomes of Venetoclax Therapy in Patients with Relapsed/Refractory (r/r) Non Hodgkin Lymphomas (NHL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018